CS-4771 Phase 1 study - A randomized, double-blind, placebo-controlled, continuous IV infusion for 96 hours, ascending dose study to assess the safety, pharmacokinetics and pharmacodynamics of CS-4771 in Japanese healthy subjects -

Trial Profile

CS-4771 Phase 1 study - A randomized, double-blind, placebo-controlled, continuous IV infusion for 96 hours, ascending dose study to assess the safety, pharmacokinetics and pharmacodynamics of CS-4771 in Japanese healthy subjects -

Completed
Phase of Trial: Phase I

Latest Information Update: 15 Jun 2016

At a glance

  • Drugs CS 4771 (Primary)
  • Indications Sepsis
  • Focus Pharmacodynamics; Pharmacokinetics; Therapeutic Use
  • Sponsors Daiichi Sankyo Company
  • Most Recent Events

    • 15 Jun 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top